The 340B rebate pilot doesn't reach what ACP is asking for.

HRSA's revised 340B Rebate Model Pilot, announced July 31, 2026, and the American College of Physicians' April 2026 policy brief in Annals of Internal Medicine are both reform efforts aimed at the same $100 billion program. They are not aimed at the same problem. HRSA is fixing a manufacturer-side transparency gap. ACP is asking for accountability on the covered entity side. Reading the two together, the pilot leaves ACP's core recommendation untouched.

What HRSA changed

The Rebate Model Pilot gives qualifying manufacturers a voluntary path to deliver the 340B ceiling price through post-claim rebates instead of upfront discounts, for a limited set of covered outpatient drugs. Manufacturers validate eligible claims, then rebate. HRSA frames this as a transparency and integrity fix built on transaction-level verification, better prevention of duplicate discounts, and support for nonduplication with the Medicare Drug Price Negotiation Program. The revision followed an RFI that drew more than 2,400 comments. Eligible manufacturers must submit rebate plans by August 24, 2026, with selected plans effective January 1, 2027.

The rationale is scale. The program grew from $53.7 billion in 2022 to more than $100 billion in 2025, and HRSA's read is that growth in covered entity sites, contract pharmacy arrangements, and specialty pharmaceuticals has outpaced the oversight infrastructure built for a smaller program. A claims-based rebate model gives HRSA a transaction record it does not currently have, at the point where the manufacturer delivers the discount.

What ACP is asking for

ACP's brief targets a different point in the value chain entirely. Its core concern is covered entity behavior, specifically the use of 340B margin to fund outpatient practice expansion into higher-income, better-insured communities, where the same discounted drug purchase now sits behind a better-reimbursed claim. That is not a manufacturer transparency problem. It is an incentive problem inside the covered entity.

ACP's recommendations follow from that diagnosis. Benefits generated by the program should be demonstrably redirected to the population the program exists to serve. Entities that do not meet that bar, or do not meet program requirements more broadly, should lose 340B eligibility. Contract pharmacies need more oversight and auditing, specifically to keep them from imposing excessive payment pressure on the covered entities they serve. And federal regulators need clearer statutory authority and more resourcing to actually enforce any of this.

Where the pilot lands, and where it doesn't

Setting the two efforts side by side shows how little they overlap. HRSA moves on the manufacturer leg of the transaction. ACP is describing a problem that lives one leg further down, inside the covered entity and its contract pharmacies.

There is an indirect connection worth naming. The transaction-level data HRSA will start collecting under the pilot is the kind of raw material a better-resourced regulator would need to eventually do the entity-level enforcement ACP wants. But the pilot does not create that enforcement authority, does not touch contract pharmacy conduct, and says nothing about the practice-expansion pattern that is the center of ACP's brief.

The contract pharmacy problem is already in federal court

ACP's call for more oversight of contract pharmacies is not theoretical. In May 2026, Mount Sinai, the University of Michigan, and the University of Kansas Health System filed federal lawsuits against CVS Health, Caremark, CVS Specialty, and WellPartner, alleging a scheme to divert roughly $250 million in 340B savings between 2020 and 2025. Henry Ford Health filed a similar suit in July. The mechanics alleged are consistent across the complaints. CVS's PBM and specialty pharmacy operations allegedly reclassified 340B-eligible claims after insurers had already reimbursed at full network rates, then passed hospitals a reduced 340B payment while retaining the spread. The University of Michigan complaint cites a single Stelara fill that generated roughly $25,000 through the university's own specialty pharmacy but was processed at about $18,500 through CVS Specialty, a gap the hospitals attribute to the same pattern repeated at scale.

This is precisely the contract pharmacy exposure ACP flagged. Covered entities depend on a vertically integrated PBM for 340B remittance, with no independent way to verify the spread between what the PBM collected and what it passed through. The hospitals are seeking a full accounting and disgorgement, which is another way of saying they want the receipts HRSA's rebate pilot does not require anyone to produce. The pilot governs the manufacturer-to-covered-entity leg of the transaction. It has nothing to say about what happens on the covered-entity-to-contract-pharmacy leg, which is where CVS is accused of taking its cut.

Where the GENEROUS model fits

CMS's GENEROUS model, a voluntary Medicaid most-favored-nation pricing model launched under CMMI authority and running 2026 through 2030, adds a third rebate architecture to the picture alongside the 340B pilot and the IRA's Medicare inflation rebate and negotiation programs. CMS has been explicit that GENEROUS operates through supplemental Medicaid rebates and is designed not to touch 340B ceiling pricing. Taken on its own terms, it is a parallel track, not a merger point.

But the direction of travel across CMS and HRSA is now uniform. Medicare, Medicaid, and 340B are all migrating toward post-claim rebate settlement instead of upfront discounting, run by three different agencies on three different timelines with three different definitions of an eligible claim. Every one of those seams, meaning which claims are 340B-eligible versus MFP-eligible versus GENEROUS-eligible, and who reconciles overlap, is a place where a PBM or specialty pharmacy sitting in the middle of the transaction can do exactly what CVS is accused of doing on a smaller scale today. If HRSA's pilot expands, as HRSA has signaled it might, the number of rebate-based settlement layers a contract pharmacy touches only grows. That raises the stakes on ACP's ask for statutory audit authority.

The practical read

For anyone advising a manufacturer, health system, or specialty society on 340B strategy, the sequencing matters. HRSA has moved first, and it moved on the piece of the program it has clearest authority over, the mechanism by which manufacturers deliver the ceiling price. The covered entity accountability question ACP is pushing on, meaning eligibility standards, contract pharmacy conduct, and statutory enforcement authority, remains open, and it is a legislative and regulatory lift that sits outside what a rebate pilot can do on its own. The CVS litigation is a preview of what that enforcement gap looks like in practice, and the expanding rebate architecture across Medicare, Medicaid, and 340B means the gap is getting wider, not narrower, while it stays open. Organizations building a 340B compliance or advocacy position for 2027 should treat these as two separate fronts, not one reform effort with two headlines.

All views, analyses, and frameworks presented here reflect independent professional judgment informed by more than two decades of experience across payer strategy, clinical transformation, and health system operations. They do not represent the views or positions of any current or former employer or affiliated organization. Nothing in this analysis constitutes legal advice.